Massachusetts General Hospital
The Neurotherapeutics Ecosystem at Mass General
Learn more about our neurotherapeutics ecosystem. Here you will find our clinical and research endeavors that show the breadth and depth of the neurotherapies across Mass General.
The NCRI develops, designs, supports and manages innovative observational and interventional trials for neurological disorders.
The CTNI offers psychiatric services that include site selection for your clinical trials, establish scientific advisory boards, assist in POC trial designs and review clinical developmental plans.
The IBC facilitates the discovery, development, and implementation of promising therapeutics and associated diagnostics for neurological, psychiatric, and neurosurgical disorders and technologies.
Focusing on Patients to Find Cures
Our multi-disciplinary approach combines the highest level of patient care with Mass General’s world class neurotherapeutics research endeavors.
Collaboration in Developing New Cell Therapy
Mass General physicians in the Departments of Neurosurgery and Neurology developed a new cell therapy using a patient’s own stem cells to treat Parkinson’s disease.
Improving Depressive Symptoms and Neuromodulation Technology
Here, Joan A. Camprodon, MD, PhD, discusses how he is using neuromodulation technology in his research to create individualized treatments for depression
Accelerating Diagnoses to Identify Treatments for ALS
Merit E. Cudkowicz, MD, MSc, chief of the Department of Neurology and director of the Sean M. Healey & AMG Center for ALS, discusses the importance of accelerating diagnoses for ALS and the new advances in therapeutic development to treat this disease.
Using Immunotherapy to Treat Brain Tumors
William Curry, MD, co-director of Mass General Neuroscience, discusses using a personalized approach to vaccinating patients with their own tumor cells, which has demonstrated strong immune activity and safety in the lab.
Finding Better Treatments for Depression
Maurizio Fava, MD, the psychiatrist-in-chief, discusses the challenges of current medications to treat depression and his work to find better options.
Mass General's neurotherapeutic development research program is situated among one of the world’s largest neuroscience, clinical and biotech communities.
Unparalleled Research Capabilities
We push scientific boundaries by training the best minds in the world
Massachusetts Biotech Ecosystem
Worlds largest concentration of biotechnology and research centers.
Mass General has 1,200 clinical trials taking place at any given time.
We focus on modern and emerging therapies including electroconvulsive therpay (ECT), vagus nerve stimulation (VNS) and functional neurosurgery.
Are you planning on receiving ECT treatments for depression? Are you interested in getting an MRI scan of your brain? If you answered yes, you may be eligible for our study.
Investigating a novel treatment for bipolar depression in older adults aged 55 and older.
Support Mass General Neurotherapeutics
Massachusetts General Hospital Neuroscience clinical trials seeks to prevent and treat brain based diseases while advancing the development of novel therapies.